The immune system and response to HER2-targeted treatment in breast cancer.

@article{Bianchini2014TheIS,
  title={The immune system and response to HER2-targeted treatment in breast cancer.},
  author={G. L. Bianchini and Luca Gianni},
  journal={The Lancet. Oncology},
  year={2014},
  volume={15 2},
  pages={e58-68}
}
The monoclonal antibody trastuzumab targets the growth factor receptor HER2 and has profoundly improved the course of disease and survival of women with HER2-overexpressing breast cancer. Because trastuzumab targets aberrant expression of HER2 in tumours addicted to HER2 activation, its clinical activity is credited largely to inhibition of intracellular signalling. A growing body of preclinical and clinical evidence shows that the immune system contributes substantially to the therapeutic… CONTINUE READING

From This Paper

Topics from this paper.
57 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 57 extracted citations

Similar Papers

Loading similar papers…